Loading…
Company strengthens leadership and secures funding.
KALA BIO, Inc. (KALA) has signed a $6 million securities purchase agreement and appointed David E Lazar as its new Chief Executive Officer. The agreement provides the company with additional funding, while the leadership change aims to strengthen its strategic direction.
The securities purchase agreement involves a $6 million investment. David E Lazar's appointment as CEO is effective immediately, bringing new leadership to the biotechnology firm.
KALA BIO has a free float of 8,166,900 shares and 10,729,700 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.